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Somatic gene therapy has been proposed as a means 
of treating inherited diseases involving defective or 
absent plasma proteins, viral diseases, and cancer. 
Introduction of the gene of interest into fibroblasts 
and implantation of these genetically modified fibro-
blasts using a skin equivalent system may be an 
attractive model for gene therapy because skin fibro-
blasts are easily obtained and propagated in culture. 
This study evaluated expression of the gene for hu-
man transferrin (hTf) by genetically modified fibro-
blasts in vitro and in vivo. NIH 3T3 fibroblasts , which 
form non-metastasizing tumors in athymic mice, 
were transduced with a retroviral vector encoding 
hTf. The transduced cells were cloned b y limiting 
dilution and hTf production b y the cloned cells mea-
sured. Two clones of cells p roducing h igh levels of 
omatic gene therapy in which a specifIC gene is intro-
duced into cells of the host has been proposed as a means 
of treating inherited deficiencies or defects in plasma 
proteins (e .g ., hemophilia), as well as many acquired 
diseases such as cancer. Somatic cells that are potential 
targets for introduced genes (transgenes) include hematopoietic 
cells, hepatocytes, myoblasts, endothelial cells, keratinocytes, and 
fibroblasts [1-7]. Current gene- therapy protocols that have been 
approved for human trials target hematopoietic, hepatic, and cancer 
cells for genetic modification [8]. Skin fibroblasts are particularly 
well suited as target cells because they are easily obtained from the 
host by skin biopsy, do not undergo differentiation i11. vitro or i11. vivo, 
and are easily propagated and genetically modified i11. vitro. After 
transduction, genetically modified fibroblasts can be simply im-
planted into and removed from the host. 
Somatic gene therapy in which therapeutic genes are introduced 
into skin cells-fibroblasts or keratinocytes-is still in the pre-
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Abbreviation: hTf, human transferrin. 
hTf were used to seed collagen-coated nylon matri-
ces, which were maintained in culture for up to 53 d. 
The rate of synthesis of hTf by the seeded matrices 
was constant after 22 d in vitro. Matrices seeded with 
cloned, transduced cells were implanted subcutane-
ously into seven athymic mice, and plasma levels of 
hTf were assessed biweekly. In all animals, the 
plasma level of hTf was detectable at week 6 after 
implantation. Levels of hTf remained elevated in the 
animals until the implants were removed at week 12. 
At week 10, the level ofhTfin the plasma correlated 
with tumor volume in tumors less than 2000 mm3 in 
size. The half-life of hTf in the mice was 39.5 h. In 
this model, gene expression did not decline for the 
12-week observation period. Key words: skin equivalents/ 
retrovirus/vectors. ] Invest Dermatol 104:171-176, 1995 
clinical, developmental phase. Essential elements of gene therapy 
include identification, isolation, and expression of the gen e of 
interest; efficient delivery of the gene into the target cells; and 
adequate and sustained expression of the gene product in vivo. 
Many genes involved in inherited diseases have been identified to 
date, and it is expected that within the next 5- 10 years most 
diseases with single-gene defects will be characterized on a molec-
war level. 
Recombinant retroviruses have been studied widely as a highly 
efficient system to integrate genes into the genome of the somatic 
cells. Recombinant retroviruses are produced by introducing the 
retroviral vector into a specialized packaging cell line, which 
produces replication-defective retroviruses encoding the gene of 
interest. These recombinant retroviruses have an amphotropic host 
range; i.e., they can infect a wide range of mammalian species [9]. 
Cellular proliferation is necessary for retroviral infection and inte-
gration (transduction), and the efficiency of transduction of target 
cells has been reported to approach 100% in some systems [10]. 
Ideally, integration of the recombinant vector into the h ost genome 
reswts in permanent expression of the introduced gene, although 
sustained expression of these genes has been difficwt to accomplish 
in animal models [11- 13]. 
Despite recent advances, many issu es rem ain to be addressed 
before somatic gene therapy can be used m ore widely in the 
treatment of disease. M ethods to maximize transgen e expression 
and delivery in vivo and the pharmacokinetics of th e transgene 
0022- 202X/95/$09.50 • SSDIO022-202X(94)00287-H • Copyright © 1995 by T he Society for Investigative D ennatology, Inc. 
171 
172 PETERSEN ET AL 
product are specific issues addressed in this study, which examines 
a gene-therapy model system using a recombinant retrovirus en-
coding the gene for human transferrin (hTf). The target cells, NIH 
3T3 fibroblasts, were modified genetically using the recombinant 
retrovirus, and clones of transduced cells producing high levels of 
hTf were isolated. A shuttle system consisting of a collagen-nylon 
matrix seeded with the transduced, cloned 3 T3 cells was implanted 
subcutaneously into athymic mice, plasma levels of hTf were 
measured, and the pharmacokinetics of hTf in the mouse were 
determined. 
MATERIALS AND METHODS 
Retroviral Vector and Packaging Cell Line A recombinant retrovirus 
derived from the Moloney murine leukemia virus was made to encode hTf 
using a cDNA from hTf obtained from Dr. R. MacGillivray (University of 
British Columbia, Vancouver, Canada). To accomplish this , a two-step 
procedure was used to remove the 5' and 3' noncoding regions of the 
transferrin cDNA. A fragment from the 3' end of transferrin (Pstl to Acel) 
was isolated and inserted into a pGEM cloning vector digested with Pstl and 
BamHl. The fragment was inserted along with two complementary syn-
thetic oligonucleotides (5' agccttaaagatct 3' and 5' gatcagatctttaaggt 3'), 
which when annealed have ends compatible with Acel and BamHl sites 
and also create a synthetic Bgi II site just after the translational stop codon. 
This 3 ' fragment was isolated from the subclone (Pstl to Bgi II) and inserted 
into the Ncol/BamHl site of the MFG retroviral vector [3] as part of a 
four-part ligation, which included a fragment from the 5' end of the 
transferrin cDNA (Ban2 to Pstl) and two complementary synthetic oligo-
nucleotides. These oligonucleotides (5' catgaggctcgccgtgggagcc 3 ' and 5 ' 
cccacggcgagcct 3') anneal to form a synthetic fragment that has ends 
compatible with Ncol and Ban2 sites. The translational start codon (atg) of 
the Ncol site corresponds to the translational start codon of the transferrin 
open reading frame: thus , the 5' non-coding sequences are removed from 
the cDNA. The assembled vector was verified by restriction enzyme 
analysis, and the 5' and 3' ends of the gene were verified by DNA 
sequencing (Fig 1). 
This retroviral vector (MFG-hTf) was introduced into the 'l'CRlP 
packaging cell line by co-transfection with pSV2 His, a plasmid that confers 
resistance to histidinol [14,15]. Two days after transfection, the cells were 
split into selective media (medium minus histidine with 1 mM histidinol) . 
Histidinol-resistant clones were isolated, expanded, and screened for the 
production of retrovirus encoding hTf. 
The packaging cell line was cultured in Dulbecco' s modification of 
Eagle's medium (DME) (Sigma, St. Louis, MO) with 10% bovine calf serum 
(Gibco , Grand Island, NY). Virus-containing medium was harvested from 
each of the clones after they reached confluence in a 24-well dish; 8 J-Lg/ml 
polybrene (Sigma) was added, and the medium was used to infect another 
24-well dish into which 1 X 104 3T3 cells had been plated the previous day. 
The cells were refed after 48 h, and the conditioned medium containing 
transferrin secreted by the infected 3T3 cells was collected 24 h later and 
frozen. The level of hTf in the conditioned medium was measured by 
enzyme-linked irnmunosorbent assay (ELISA) (see below). The clone of the 
packaging cell line producing the highest level of recombinant virus was 
identified by the highest level of transferrin production in the media of the 
infected 3T3 cells. This clone (designated T38) was expanded further and 
used as the packaging cell line for the experiments described below. 
Transduction of 3T3 Fibroblasts Nonconfluent cultures of 3T3 fibro-
blasts, grown in DME with 10% bovine serum, were incubated at 37°C in 
undiluted T38-conditioned medium containing 8 J-Lg/ml polybrene. Mter 
overnight incubation, the cells were incubated in fresh T38-conditioned 
medium with 8 J-Lg/ml polybrene for 2 h. Following this incubation, the 
cells were grown to confluence in DME with 10% calf serum. Upon 
Nco I BamH 1 
~LTR LTR i'w'-'1'+ Human Transferrin 
Figure 1. Schematic representation of the retroviral construct, 
MFG-hTf. The gene encoding hTfwas inserted after the 5 ' long terminal 
repeat (LTR) promoter sequence and an extended retroviral packaging 
signal ('1'+), as described in Materials and Methods. 
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confluence the medium was changed, and after 24 h the medium was 
assayed for hTf with ELISA. 
Clonal Expansion ofhTf-3T3 Fibroblasts Cultures of transduced 3T3 
cells producing high levels of hTf (designated hTf-3T3) were cloned by 
limiting dilution into 24-well plates. Eight clones expressing high levels o j 
hTf were expanded in 60-mm culture dishes. The two clones producing tht 
highest levels of hTf were used to seed the dermal matrices. 
Preparation ofhTf-3T3/Collagen Matrices Nylon mesh matrices. 1.2 
cm2, were obtained from Advanced Tissue Science (La Jolla, CA). Thes 
matrices are seeded and "conditioned" with 25 X 106 human neonatal 
dermal fibroblasts by the manufacturer. After 2-3 weeks, the neonatal 
fibroblasts were lysed hypotonically as follows: the matrix was rinsed with 
sterile water, covered with sterile water, and stored overnight at - 70°C , 
thawed, and rinsed twice with sterile water. The "conditioned" matrices. 
containing no viable cells, were shipped frozen in DME. Matrices were 
stored at -20°C before seeding with cloned hTf-3T3 fibroblasts. For 
seeding, the matrices were placed in six-well tissue culture plates and 
thawed. Cloned hTf-3T3 cells were dissociated with 0.025% trypsin-
ethylenediamine tetraacetic acid, and 1 X 106 cells in 50 J-LI DME with 10% 
bovine calf serum were pipetted onto the top of each matrix. The matrices 
then were incubated at 37°C to allow the cells to migrate into the matrix. 
After 3 h, 4 ml ofDME with 10% bovine serum was added to each well. and 
the plates were incubated overnight at 37°C. The next day, the medium was 
removed and a second 50-J-LI aliquot of 1 X 106 cells was added to each 
matrix for 3 h, after which the matrices were refed with 4 ml of DME with 
10% bovine calf serum. These hTf-3T3/ collagen matrices were maintained 
in culture for 11-53 d in DME with 10% bovine calf serum at 37°C. 
Conditioned medium was collected every third day from these cultures and 
assayed for hTf. 
Implantation of 3T3/Collagen Matrices Two 3T3/ collagen matrices, 
which had been maintained in culture for 53 d , were bisected and implanted 
subcutaneously in both thoracic flanks of two athymic (Balb/c nu/nu) adult 
mice (Charles River Laboratories, Wilmington, MA). Similarly, matrices 
maintained for 11 d in culture were implanted unilaterally into five mice. 
Two mice were implanted with matrices that had not been seeded with 
cells, and one animal was implanted with a matrix seeded with 3T3 cells 
transduced with a retrovirus encoding J3-galactosidase. Matrices were 
attached to the overlying skin with a surgical staple. After 1 week, the 
staples were removed and the matrices remained fixed in the subcutaneous 
space. 
Matrices seeded with non-transduced 3T3 fibroblasts form tumors when 
implanted in athymic mice [16]. The animals were inspected weekly for 
tumor growth, and tumor volume was estimated from calipers measure-
ments of the tumors in situ at week 10 and upon removal of the tumors at 
week 12. 
hTf Levels in Grafted Mice Experimental animals were bled from the 
tail vein before implantation of the 3T3/ collagen matrices and at biweekly 
intervals post-transplantation. The blood was centrifuged and the serum 
assayed for hTf with ELISA. 
ELISA for hTf The concentration ofhTfin the conditioned medium and 
the plasma of the mice was measured with a standard competition ELISA. 
Wells of flat-bottom microtiter plates were incubated overnight with 
purified human apotransferrin (0.4 J-Lg/well, Sigma) in Voller's buffer. 
Duplicate samples of human apotransferrin, 0.1 J-Lg/I00 J-LI, and the samples 
were added to round-bottom micro titer plates and dilu ted serially. Goat 
anti-hTfantibody (100 J-LlIwell, Organon Teknika Corp. , Westchester, PA) 
was added to each well for a final dilution of 1: 1 0,000, and the plates were 
incubated overnight at 4°C. The contents of the round-bottom wells were 
transferred to the antigen-coated plates and incubated for 2 h at 25°C. These 
plates were then washed, and 200 J-LI of rabbit anti-goat IgG (1:1000, 
Organon Teknika) was added to each well for 90 min at 25°C. Phenylenedi-
amine dihydrochloride was used as the substrate solution, and absorbance 
was measured at 490 nm. The lower limit of detection of this assay was 
estimated as 0.5 J-Lg/ ml. 
Southern Blot Hybridization DNA was extracted from the cells using 
standard techniques [17]. DNA digests were prepared using the restriction 
endonuclease PST 1 (Boehringer Mannheim Corp., Indianapolis, IN) . 
Digests were run on an agarose gel, transferred to S&S Nytran Plus 
membranes (Schleicher & Schuell, Inc., Keene, NH), hybridized with 
32P-Iabeled hTf eDNA, washed, and reprobed with a radiolabeled control 
cDNA, v-fos (Clontech Laboratories, Inc., Palo Alto, CA), which yields a 
single band in mouse DNA digested with PST 1. Autoradiograms were 
analyzed using a Bio-Rad GS-250 Molecular Imager, and a ratio of the hTf 
signallv-fos signal for each sample was calculated. 
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Figure 2. Levels of hTf produced by cloned hTf-3T3 fibroblasts. 
3T3 fibroblasts were transduced with a retroviral vector encoding the gene 
for hTf. After transduction, the cells were cloned by limiting dilution into 
24-well plates. Wells displaying evidence of clonal growth were grown to 
confluence, and hTflevels in the conditioned medium were measured with 
ELISA. The distribution of these levels is shown. The number at the end of 
each bar is the number of clones producing hTf within the range specified. 
A majority (53%) of the clones produced hTf above the detection limit of 
0.5 /-Lg/ml. Eight clones producing high levels ofhTf (0.9-1.3 /-Lg/ml) were 
expanded in culture. 
RESULTS 
hTf-3T3 Cells Produce Measurable Levels ofhTfin Culture 
After transduction with the hTf retrovirus and upon reaching 
confluence, the transduced 3T3 cells were found to produce 
0.10-0.92 J.Lg/ml/24 h ofhTf. Two cultures, producing 0.89 and 
0.92 J.Lg/ml/24 h, were cloned by limiting dilution. Levels ofhTf 
were measured in the 77 wells (of 144) that demonstrated clonal 
growth. The levels of hTf in these cultures are shown in Fig 2 and 
ranged from 0.00 to 1.34 J.Lg/ml. Eight clones producing high levels 
of hTf (0.95-1.34 JLg/ml) were expanded into 60-mm culture 
dishes. Two of the expanded clones (BTl-4C, BT4-3B) were 
found to produce especially high levels of hTf (5.53 and 4.99 
J.Lg/ml, respectively) and were used to seed the collagen matrices. 
No hTfwas detected in the supernatants from non-transduced 3T3 
cells or in supernatants from cultured human neonatal and adult 
fibroblasts (data not shown). 
The wide range of hTf produced by the cloned cells was 
intriguing. We hypothesized that the clones producing high levels 
of hTf had multiple copies of the hTf gene integrated into their 
genome. To test this, we performed Southern blot hybridization on 
DNA extracted from a high-producing and a lower-producing 3T3 
clone; from transduced, non-cloned 3T3 cells; and from unmodi-
fied 3T3 cells (Fig 3). The signals from these samples were 
compared with the signals generated using 3T3 DNA "spiked" 
with known quantities of the cDNA corresponding to the hTf gene. 
The intensity of the hTf signals from both clones (lanes 6 and 7), the 
non-cloned transduced 3T3 cells (lane 8) , and the 3T3 "spiked" 
with 10 pg of hTf cDNA (lane 3) were approximately equal. This 
amount ofhTf cDNA, 10 pg, is equivalent to two copies of the hTf 
gene per cell. Therefore, because the two 3T3 clones had inte-
grated the same number of copies of the hTf gene (n = 2), the 
difference in transferrin production was not due to the presence of 
a greater number of gene copies. Thus, we hypothesize that the hTf 
retrovirus may have integrated into more transcriptionally active 
and stable sites in the clones producing higher levels of hTf, 
resulting in higher gene expression in these cells. 
hTf-3T3/Collagen Matrices Produce hTf for 53 d In Vitro 
As stated previously, collagen matrices were seeded with cells 
derived from the BTl-4C and BT4-3B clones. The seeded matrices 
were maintained in culture for 53 d, and the rates of hTf produced 
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by these matrices were measured (Fig 4). Mter seeding, the rate of 
hTf synthesis increased initially during the first 3 weeks in culture, 
then remained relatively constant from day 22 to the end of the 
experiment at day 53. Appreciable concentrations of hTf (0.3 
J.Lg/ml) were measured per 24-h period in both matrices. 
Because the concentration ofhTfin the medium reflects the rate 
of synthesis less the rate of degradation, the degradation rate ofhTf 
in the medium was determined. Radiolabeled hTf C2sI-hTf) was 
added to the medium of cultured hTf-3T3/collagen matrices. Mter 
30 h, the amount of trichloroacetic-acid-soluble radioactivity in the 
conditioned medium was measured. No radioactivity was detected 
in the trichloroacetic-acid-soluble fraction over this period; there-
fore, the 12sI_hTf was metabolically stable and not degraded under 
these culture conditions. Thus, the concentration of hTf in the 
medium of the cultured hTf-3T3/collagen matrices accurately 
reflected the rate of synthesis. 
We found the rate ofhTf synthesis in culture to be reproducible 
in a second group of five matrices seeded with cells of the BTl-4C 
clone. Media from these seeded matrices were collected at day 11 
in vitro, pooled, and assayed for hTf. The rate of synthesis ofhTfin 
these cultures was 0.33 J.Lg/m1l24 h on day 11. This rate was 
comparable to the synthesis rate on day 11 measured in the initial 
set of two matrices (0.2 J.Lg/m1l24 h), as shown in Fig 4. Because 
it was not possible to measure accurately the number of cells 
populating the matrix, the rate of production per cell could not be 
A. lanes 1 2 3 4 5 6 7 8 
1 2 3 4 5 6 7 8 
B. 
c. 1 2 6 8 3 4 5 7 RATIO 
hTf/V-fos 0.02 1.34 2.75 3.96 5.44 2.73 2.18 1.81 
Figure 3. Two copies of the hTftransgene were integrated into the 
3T3 cells. DNA was extracted from the cells and digested with PST 1, and 
Southern blotting was performed (see Materials and Methods). The blots were 
hybridized with radiolabeled cDNA corresponding to the hTf gene (A) and 
reprobed with a control gene, v-fos (B). Lane 1, DNA extracted from 
non-modified 3T3 cells; lane 6, DNA from a "high-producing" clone of 
transduced 3T3 cells; lane 7, DNA from a "lower-producing" clone of 
transduced 3T3 cells; lane 8, DNA from transduced but non-cloned 3T3 
cells. Lanes 2-5, DNA from non-modified 3T3 cells to which known 
quantities ofhTf cDNA had been added (5, 10,20, and 30 pg, respectively). 
In this case, 10 pg of hTf cDNA corresponds to two copies of the hTf gene. 
Comparison of the ratios of hTf to v-fos (C) reveals similar values from the 
two clones of transduced cells (2.73, 2.18) and the 3T3 cDNA "spiked" 
with 10 pg hTf DNA (2.75). Thus, the difference in gene expression 
between the two different clones of transduced 3T3 cells was not due to a 
difference in the number of copies of the trans gene integrated into the 
genome of the 3 T3 cells. 
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Figure 4. Rate of hTf synthesis in culture by cloned hTf-3T3 
fibroblasts seeding a collagen matrix. Two clones of transduced 3T3 
fibroblasts (BTl-4C, circles; BT4-3B, diamonds) were expanded and used to 
seed "conditioned" collagen matrices (see Materials and Methods). The 
concentration of hTf produced by each seeded matrix per 24 h is shown. 
The dashed line represents a best-fit curve for the two matrices . The rate of 
synthesis of hTf rose rapidly in the first 3 weeks, then remained relatively 
stable for the duration of the experiment (53 d). 
detennined. However, morphologic observations suggest that the 
number of cells in the matrix does not increase appreciably after 
3-4 weeks in culture. Thus, we conclude that the transduced, 
cloned cells maintained their rate of production of the gene product 
for an extended period in culture. 
hTf Was Detected in the Plasma of Athymic Mice Im-
planted With hTf-3T3/Collagen Matrices After 53 d in vitro, 
hTf-producing matrices were implanted subcutaneously into two 
athymic mice. Plasma levels of hTf in the mice were assayed at 
biweekly intervals. In no instance was hTf detected in the plasma of 
mice implanted with non-seeded matrices or in the mouse im-
planted with a matrix seeded with 3T3 cells transduced with a 
retrovirus encoding {3-galactosidase. 
Low levels of hTf were measured at 2-6 weeks in the two 
experimental mice (Fig 5). Subsequently, increasing amounts of 
hTf were detected at 8-12 weeks, such that the concentration of 
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Figure 5. Plasma levels of hTf in two mice implanted with matri-
ces maintained in culture for 53 d. Two matrices seeded with cloned 
hTf-3T3 cells (BT1-4C, circles; BT4-3B, diamonds) that had been maintained 
in culture for 53 d (Fig 4) were implanted subcutaneously into two athymic 
mice. Plasma hTf levels were assessed biweekly after implantation. The 
plasma level of hTf was low for 6 weeks, then increased until the matrices 
were removed at week 12. The increase in hTf paralleled the development 
of tumors at the site of implantation (see Results). The concentration ofhTf 
at week 12 equaled 30 fLg/ml (4.0 X 10- 7 M), a level comparable to that 
seen in human plasma. After removal of the matrices, plasma hTffell rapidly 
and was essentially nondetectable within 4 d. 
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Figure 6. Plasma levels ofhTfin five mice implanted with matrices 
maintained in culture for 11 d. Five mice were implanted with matrices 
seeded with the BTl-4C clone of transduced cells 11 d before implantation. 
As in the first two animals (Fig 5), plasma levels ofhTf remained low for the 
first 6 weeks post-implantation. The level of hTf increased between weeks 
6-8 in all animals and appeared to plateau after week 8 in three of the five 
animals. Levels of hTf were comparable to those seen in the animals 
implanted with the 53-d matrices (Fig 5). The implant was removed from 
one animal at week 10 (downward triangles), and plasma hTfwas measured 4 
d after removal. Plasma levels of hTf were obtained in two additional 
animals 4 d after tumor removal at 12 weeks. The concentration of hTf in 
the plasma fell rapidly after tumor removal in the three remaining animals. 
Two animals died at week 12 before tumor removal. 
plasma hTf was 30 J.Lg/ml (4.0 X 10- 7 M) at week 12. The 
concentration of hTf continued to increase throughout the exper-
iment. Endogenous levels of transferrin are approximately 200 
J.Lg/ml in normal mice and less than 20 J.Lg/ml in hypotransferrine-
mlC mIce. 
Matrices seeded with cloned hTf-3T3 cells and maintained in 
culture for 11 d were implanted into five additional mice. In these 
animals, little plasma hTf was detected before week 8 (Fig 6), an 
observation consistent with the results from the experiment using 
two mice implanted with the 53-d matrices. After week 8, all 
animals showed measurable levels of hTf. There was variation in 
terms of the absolute levels of hTf measured in individual animals 
and the times at which a given level was observed. However, all 
seven mice implanted with hTf-expressing matrices demonstrated 
similar peak levels of hTf (Figs 5, 6). 
In these experiments, athymic mice implanted with matrices 
seeded with 3 T3 fibroblasts developed tumors at the site of the 
implants, possibly due to genetic instability of the 3T3 cells and the 
abnormal immune system of the athymic mice. Tumor develop-
ment was not dependent on transduction of the 3T3 cells, as 
matrices seeded with cloned, non-transduced 3T3 cells also pro-
duced tumors (G.G. Krueger, unpublished observation, 1994). At 
week 12, tumors were removed from the mice implanted with 
hTf-producing matrices, and the half-life (tl 12) of hTf in vivo was 
determined by measuring plasma hTf at 24, 48, and 96 h after 
tumor removal in three animals. The average t ll2 was 39.5 h (Fig 
7), as calculated from the slope of the exponential curve of the 
disappearance ofhTf from plasma (t1l2 = In 2/slope). The half-life 
of hTf measured in the grafted mice was very similar to that in 
normal and hypotransferrinemic mice after intraperitoneal injection 
ofhTf (tll2 = 33 h; J. Kaplan, unpublished observation, 1991). 
Plasma hTfLevels Correlclte With Tumor Size The relation 
between plasma level of hTf and tumor volume was analyzed at 
week 10 (Fig 8). In animals with tumors less than 2000 mm3 in size 
(closed circles), plasma levels of hTf correlated with the size of the 
tumor (r2 = 0.93). In animals with larger tumors (volume greater 
than 2000 mm3 ; open circles), plasma hTf did not increase propor-
tionately, and there was little correlation between the hTflevel and 
tumor volume. Histologic examination demonstrated cystic spaces 
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Figure 7. The half-life of hTf in three mice after removal of the 
implants was 39.5 h. A) Plasma levels of hTf were measured 24 48 and 
96 h after removal of the implants in three animals. The half-life ~f hTf in 
each animal was calculated (t1l2 = In 2IB; B = slope of exponential curve). 
B) The average of the three curves in A is shown. The average half-life of 
hTf was 39.5 h. 
within t~e larger tumors. Thus, beyond a certain volume, larger 
tumor SIze does not reflect an increased number of cells. These 
observations suggest that hTf production was dependent on cell 
number as opposed to tumor volume. 
DISCUSSION 
Genetic modification and transplantation of skin cells has been 
proposed as a means of supplying deficient plasma proteins, as well 
as other cellular products such as cytokines [12,13,18]. Key factors 
to t~s approach include isolation and culture of the target cells, 
effiCIent transduction of the genetic material of interest, transplan-
tation of the genetically modified cells into the host, and long-term 
expression of the introduced gene product in the host. This study 
explored these factors in detail. 
A retroviral vector containing the gene for hTfwas used in these 
experiments. The hTf gene was selected in conjunction with 
ongoing research efforts of one of the authors OK) examining iron 
metabolism and hemochromatosis using a hypotransferrinemic 
mouse model [19]. Recombinant retroviruses are used widely in ex 
vivo gene-transfer studies because of the high transduction effi-
ciency of many target cells and integration of the gene of interest 
into the genome of the target cells. The rate of transduction of the 
3T3 cells was 53% (41 of 77) in our study, extrapolating from the 
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Figure 8. Plasma hTf correlates with tumor size up to 2000 mm3 • 
T~mor ~ize was measured at week 10 in all seven experimental animals. In 
nuce WIth smaller tumors (closed circles), the plasma concentration of hTf 
correlated closely with tumor size (r2 = 0.93). As the tumors enlarged and 
~ecame centrally cystic (open circles), hTf no longer correlated with tumor 
SIZe. 
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total number of clones expressing hTf at 0.5 J.Lg/ml (the lower limit 
of detection in the assay) or greater. Although this represents an 
acceptable transduction efficiency, we chose to clone the trans-
duced cells to seed the matrices exclusively with cells expressing 
hTf, thereby maximizing production in vivo. 
Mter the dermal matrices were seeded with a clonal population 
of transduced 3T3 cells, the rate of hTf production in vitro was 
relatively constant after 22 d. This suggests that the matrices were 
populat~d with a maximum number of transferrin-producing fibro-
blasts after 3 or more weeks in culture. More important, as 
demonstrated in the matrices maintained in culture for 53 d, there 
was no decline in hTf levels over time; this suggests that gene 
expression was not significantly down-regulated or inactivated for 
up to 8 weeks in vitro. 
Other investigators have used implants of genetically modified 
fibroblasts within a collagen matrix as a means of administering a 
"new" gene product [6,12,13,18]. The development of tumors by 
the matrices after implantation increased the number of genetically 
modified cells per animal as a function of time, and high levels of 
hTf (30 J.Lg/ml, 4.0 X 10- 7 M) were achieved in the plasma of the 
implanted mice as the tumors enlarged. Although the concentration 
of hTf in human plasma is much higher (3 X 10- 5 M), the 
concentration of hTf in the implanted mice exceeds that required 
for hematopoeisis in humans (1 X 10- 8 M). The plasma concen-
tration of hTf correlated closely with tumor size until the tumors 
became cystic as they enlarged. Correlation of plasma levels of the 
gene product with tumor size or cell number is an important 
element of an effective gene-therapy system, as it suggests that 
blood levels can be augmented by increasing the number of 
genetically modified cells introduced into the recipient. Finally, the 
disappearance of hTf from the plasma of the mice after tumor 
removal suggests that these genetically modified cells did not 
metastasize to distant sites, another important element of an 
effective gene-therapy system. 
Expression of hTf persisted for up to 84 d in vivo in mice 
implanted with matrices maintained in culture for either 11 or 53 d. 
Thus, these transduced cells continued to express the hTf gene for 
over 130 d. Moullier et al [20] reported sustained expression of a 
transduced gene, f3-glucuronidase, for 155 d from genetically 
modified fibroblasts in a collagen lattice implanted intraperitone-
ally, as assessed by the level of enzyme activity in tissue. However, 
persistence of a transduced gene product in the plasma of trans-
planted animals has been more difficult to achieve [21]. Several 
mechanisms have been implicated in the disappearance of these 
proteins from plasma: 1) development of antibodies to the foreign 
~rot~in, .2) rapid clearance of the protein from plasma, and 3) 
mactlvatIOn or down-regulation of the vector in vivo. The persis-
tence of plasma hTf in mice implanted with matrices containing 
cloned hTf-3T3 cells suggests that such mechanisms were not 
operative in our system. The absence of T cells in athymic mice 
precludes development of antibodies directed against foreign pro-
te~s, as desc?bed in immunologically competent mice implanted 
With syngeneIC cells transduced with the gene for human factor IX 
[11]. The concentration ofhTf and its long half-life (39.5 h) in the 
implanted animals suggest that hTf was not cleared rapidly from the 
plasma in these mice. In contrast, human factor VIII was cleared 
~apidly fro~ the plasma of athymic animals implanted with genet-
~cally modIfied fibroblasts [13], presumably related to properties 
inh~re~t to fa~tor VIII that facilitate its clearance from the plasma. 
. S~ilarly, different factors are believed to mediate vector expres-
SIOn m transduced cells. As such, the integration site of the vector 
into the genomic DNA of the transduced cells may affect vector 
expression. In our study, Southern blot analysis demonstrated that 
~tegration of additional gene copies was not responsible for the 
high levels ofhTf detected in the high-producing clones relative to 
the 10': producers. Therefore, we hypothesized that the high-
producmg clones represented cells in which the viral vector had 
integrated into transcriptionally stable and active sites, leading to 
sustained expression of the trans gene product. In contrast, loss of 
gene expression, resulting from down-regulation of vector expres-
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sion, occurs over time. Down-regulation of gene expression was 
postulated to explain the disappearance of human adenosine deami-
nase from dermal equivalent grafts containing rat fibroblasts trans-
duced with the human adenosine deaminase gene, as vector 
sequences were detected for months in the grafts after human 
adenosine deaminase levels had fallen [12]. The promoter that 
drives transcription of the introduced gene also may be a key factor 
in determining long-term expression in vivo. Scharfmann et al [21] 
demonstrated prolonged expression (60 d) of a /3-galactosidase 
gene linked to a housekeeping gene promoter, dihydrofolate 
reductase, compared with that linked to a cytomegalovirus pro-
moter. In the recombinant retrovirus used in our study, the 5' 
long-terminal-repeat promoter directs transcription of the hTf 
gene. Whereas bone marrow cells transduced with retroviral 
transcripts encoding the human adenosine deaminase gene linked to 
the long-terminal-repeat promoter have expressed this gene in vivo 
for up to 5.5 months [22], expression of long-terminal-repeat-
driven genes in fibroblasts for longer than 2 months in vivo has not 
been reported [21,23]. 
In conclusion, we have analyzed a model system of gene therapy 
to correct deficiencies of plasma proteins. Important features 
demonstrated with this model include selection of a clone of cells 
producing high levels of the introduced gene product, expansion of 
this clone for use in the transplanted dermal matrices, consistent 
gene expression for over 18 weeks (130 d), and correlation of 
plasma levels with the size of the developing tumors containing the 
genetically modified cells. These findings support the hypothesis 
that autologous fibroblasts with a stable transgene that is transcrip-
tionally active are a reasonable target for genetic modification to 
correct deficiencies in plasma proteins. It also seems likely that such 
a system could be used to correct localized inherited diseases of the 
skin, with a trans gene product being delivered in a paracrine 
fashion. 
This work was supported in part by National Institutes of Health grants P01-
HD28528 (MjP,jK,jRM, GGK), R29-AR41207 (MjP), and R01-DK30534 
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ANNOUNCEMENT 
The 44th Annual Symposium on the Biology of Skin, entitled "Skin Cancer: Pathomechanisms. 
Epidemiology and Clinical Manifestations, and New Approaches to Therapy," will be held July 
11-15, 1995 at Snowmass Village, Colorado. 
This meeting will provide a comprehensive review of the cellular and molecular biology of 
carcinogenesis, the biology of skin cancers, and modern approaches to treatment. 
Formal presentations by invited speakers, invited poster presentations, and free poster presentations 
will be included. 
Abstracts for the free poster session should be submitted by May 15, 1995 on SID or ESDR abstract 
forms to: 
David A. Norris, M.D. 
44th Annual Symposium on the Biology of Skin 
Box B 144 Department of Dermatology 
University of Colorado School of Medicine 
4200 East Ninth Avenue 
Denver CO 80262. 
